Plante Moran Financial Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Plante Moran Financial Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.84K	Buy	+15	New	+$1.57K	﹤0.01%	757

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Plante Moran Financial Advisors's PTGX Position: Q2 2026 in Review

Plante Moran Financial Advisors opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 15 shares worth $1.84K. The stake represents ﹤0.01% of the portfolio and ranks #757 among its holdings.

343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Plante Moran Financial Advisors held 15 shares of Protagonist Therapeutics worth $1.84K as of Q2 2026.
Protagonist Therapeutics was a new Plante Moran Financial Advisors position in Q2 2026.
Protagonist Therapeutics made up ﹤0.01% of Plante Moran Financial Advisors's portfolio in Q2 2026, its #757 holding.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Plante Moran Financial Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.